Stanford University School of Medicine, Stanford, CA, USA.
Departments of Psychiatry, Columbia University, New York, NY, USA.
Mol Psychiatry. 2022 Jun;27(6):2689-2699. doi: 10.1038/s41380-022-01520-y. Epub 2022 Mar 30.
Major depressive disorder (MDD) was previously hypothesized to be a disease of monoamine deficiency in which low levels of monoamines in the synaptic cleft were believed to underlie depressive symptoms. More recently, however, there has been a paradigm shift toward a neuroplasticity hypothesis of depression in which downstream effects of antidepressants, such as increased neurogenesis, contribute to improvements in cognition and mood. This review takes a top-down approach to assess how changes in behavior and hippocampal-dependent circuits may be attributed to abnormalities at the molecular, structural, and synaptic level. We conclude with a discussion of how antidepressant treatments share a common effect in modulating neuroplasticity and consider outstanding questions and future perspectives.
重度抑郁症(MDD)先前被假设为一种单胺缺乏症,其中认为突触间隙中单胺水平低是抑郁症状的基础。然而,最近人们的观念发生了转变,开始认为抑郁症是一种神经可塑性假说,抗抑郁药的下游效应,如增加神经发生,有助于改善认知和情绪。本综述采用自上而下的方法来评估行为和海马依赖回路的变化如何归因于分子、结构和突触水平的异常。最后我们讨论了抗抑郁治疗如何通过调节神经可塑性产生共同的效果,并考虑了悬而未决的问题和未来的展望。